Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome

Keith Pratz, Cynthia Ma, Marie Christine Aubry, Terri J. Vrtiska, Charles Erlichman

Research output: Contribution to journalArticle

Abstract

Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas. Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer. We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide. Laboratory evaluation indicated elevated serum calcitonin and vasoactive intestinal polypeptide levels. Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers. The patient did not respond to further therapy and died 5 months after onset of back pain. To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.

Original languageEnglish (US)
Pages (from-to)116-120
Number of pages5
JournalMayo Clinic Proceedings
Volume80
Issue number1
StatePublished - 2005
Externally publishedYes

Fingerprint

Vipoma
Large Cell Carcinoma
Vasoactive Intestinal Peptide
Calcitonin
Diarrhea
Non-Small Cell Lung Carcinoma
Achlorhydria
Islet Cell Adenoma
Paraneoplastic Syndromes
Octreotide
Hypokalemia
Back Pain
Pancreas
Therapeutics
Pharmacology
Neoplasm Metastasis
Bone and Bones
Drug Therapy
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pratz, K., Ma, C., Aubry, M. C., Vrtiska, T. J., & Erlichman, C. (2005). Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. Mayo Clinic Proceedings, 80(1), 116-120.

Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. / Pratz, Keith; Ma, Cynthia; Aubry, Marie Christine; Vrtiska, Terri J.; Erlichman, Charles.

In: Mayo Clinic Proceedings, Vol. 80, No. 1, 2005, p. 116-120.

Research output: Contribution to journalArticle

Pratz, K, Ma, C, Aubry, MC, Vrtiska, TJ & Erlichman, C 2005, 'Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome', Mayo Clinic Proceedings, vol. 80, no. 1, pp. 116-120.
Pratz, Keith ; Ma, Cynthia ; Aubry, Marie Christine ; Vrtiska, Terri J. ; Erlichman, Charles. / Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. In: Mayo Clinic Proceedings. 2005 ; Vol. 80, No. 1. pp. 116-120.
@article{e9f15694cde84d71b986fbbb3df94d09,
title = "Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome",
abstract = "Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas. Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer. We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide. Laboratory evaluation indicated elevated serum calcitonin and vasoactive intestinal polypeptide levels. Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers. The patient did not respond to further therapy and died 5 months after onset of back pain. To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.",
author = "Keith Pratz and Cynthia Ma and Aubry, {Marie Christine} and Vrtiska, {Terri J.} and Charles Erlichman",
year = "2005",
language = "English (US)",
volume = "80",
pages = "116--120",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome

AU - Pratz, Keith

AU - Ma, Cynthia

AU - Aubry, Marie Christine

AU - Vrtiska, Terri J.

AU - Erlichman, Charles

PY - 2005

Y1 - 2005

N2 - Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas. Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer. We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide. Laboratory evaluation indicated elevated serum calcitonin and vasoactive intestinal polypeptide levels. Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers. The patient did not respond to further therapy and died 5 months after onset of back pain. To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.

AB - Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas. Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer. We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide. Laboratory evaluation indicated elevated serum calcitonin and vasoactive intestinal polypeptide levels. Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers. The patient did not respond to further therapy and died 5 months after onset of back pain. To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.

UR - http://www.scopus.com/inward/record.url?scp=11344276245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11344276245&partnerID=8YFLogxK

M3 - Article

C2 - 15667039

AN - SCOPUS:11344276245

VL - 80

SP - 116

EP - 120

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -